Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(Suppl 1):162-72
Article Links
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study
Gkikas Katsifis1, Athina Theodoridou2, Andreas Bounas3, Panagiotis Georgiou4, Petros Sfikakis5, Kalliopi Fragiadaki5, Theodoros Dimitroulas6, Evangelia Mole7, Lars Bauer8, Thomas Kumke8, Bengt Hoepken8
Authors Information
  1. Rheumatology Clinic, Athens Naval Hospital, Athens, Greece
  2. Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece
  3. Olympion Therapeutirion General Clinic, Patras, Greece
  4. Rheumatology Unit, Agios Andreas Hospital, Patras, Greece
  5. Laikon General Hospital, Athens, Greece
  6. 4th Department of Internal Medicine, Hippokrateion General Hospital of Thessaloniki, School of Medicine, Aristotle University, Thessaloniki, Greece
  7. Evangelismos General Hospital, Athens, Greece
  8. UCB Pharma, Monheim am Rhein, Germany


G Katsifis, A Theodoridou, A Bounas, P Georgiou, P Sfikakis, K Fragiadaki, T Dimitroulas, E Mole, L Bauer, T Kumke, B Hoepken

Keywords: axial spondyloarthritis, TNF inhibitor, certolizumab pegol
References
  1. van der Heijde D, Purcaru O, Kavanaugh A. Economic Burden of Axial Spondyloarthritis Related to Paid Work and Household Productivity at Baseline in the Rapid-axSpA Study: Differences and Similarities Between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. Value Health 2013;16:A566.
  2. Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol 2017;23:383.
  3. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford) 2004;43:615-8.
  4. Kassimos D, Papatheodorou G, Daniilidis M, Garyfallos A. 117. HLA-B27 Subtypes In A Greek Population With Seronegative Spondyloarthritis. Rheumatology 2017;56.
  5. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995;7:263-9.
  6. Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estévez E, et al. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. Rheumatology (Oxford) 2021;60:113-124.
  7. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016;18:196.
  8. Trontzas PI. Rheumatology: Necessary adjustments to the realities of the new era in Greece. Mediterr J Rheumatol 2017;28:94.
  9. Mechili EA, Nikitara K, Girvalaki C, Kyriakos C, Vardavas CI. Patient journey pain points in spondyloarthritis and psoriasis: The case of Greece. Popul Med 2019;1.
  10. Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
  11. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993;20:1900-1904.
  12. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39-47.
  13. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Dis 2010;11:1-8.
  14. Trontzas P, Andrianakos A, Miyakis S, Pantelidou K, Vafiadou E, Garantziotou V, et al. Seronegative Spondyloarthropathies in Greece: A Population-Based Study of Prevalence, Clinical Pattern, and Management. The ESORDIG Study. Clin Rheumatol 2005;24:583-9.
  15. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-991.
  16. Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology 2020;59:iv79-iv89.
  17. Sfikakis PP, Bournia V-K, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017;35:579-585.
  18. van der Heijde D, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 2018;77:699-705.
  19. van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford) 2017;56:1498-1509.
  20. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, et al. A 52–week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2019;71:1101-1111.
  21. U.S. National Library of Medicine. ClinicalTrials.gov. A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (CIMAX). https://clinicaltrials.gov/ct2/show/NCT02354105. Last accessed: 10/05/2021.
  22. European Medicines Agency. Summary of Product Characteristics (CIMZIA). https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf. Last accessed: 11/05/2021.
  23. Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 2002;181-182:71-8.
  24. Sundström B, Wållberg-Jonsson S, Johansson G. Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis. Clin Rheumatol 2011;30:71-6.
  25. Montemurno E, Cosola C, Dalfino G, Daidone G, De Angelis M, Gobbetti M, et al. What would you like to eat, Mr CKD Microbiota? A Mediterranean Diet, please! Kidney Blood Press Res 2014;39:114-23.